Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

- FDA (CDER) Type C meeting held in May 2025 for DYNE-101 in DM1 and Dyne plans to provide a regulatory update following receipt of meeting minutes -